-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
310 ，，。
，，，，。
，。Insight，3，、、（30R）、（50R）、，。
（：Insight）
，2020717，，，。
On January 29, the State Council Information Office held a regular policy briefing.
Chen Jinfu, deputy director of the National Medical Insurance Administration, further stated that: biosimilar drugs, including large varieties of proprietary Chinese medicines, are included in the centralized procurement.
This is an institutional requirement, but the rules will It is more optimized, more targeted, and the quality is more in line with the attributes of the medicine itself.
Chen Jinfu, deputy director of the National Medical Insurance Administration, further stated that: biosimilar drugs, including large varieties of proprietary Chinese medicines, are included in the centralized procurement.
This is an institutional requirement, but the rules will It is more optimized, more targeted, and the quality is more in line with the attributes of the medicine itself.
Guosen Securities pointed out in a research report that the maturity of insulin products is high, and there is a possibility of centralized procurement in the competitive landscape; and the medical insurance catalogue basically achieves comprehensive coverage of all kinds of insulin products-the second-generation insulin is included in the Class A medical insurance, and the third-generation insulin is included in the third-generation medical insurance.
Insulin is included in Class B medical insurance (with certain reimbursement restrictions); in addition, diabetic patients need to use insulin for life, with high frequency of use, large dosage, and high reimbursement ratio.
Based on the above factors, insulin may become the focus of centralized procurement.
Insulin is included in Class B medical insurance (with certain reimbursement restrictions); in addition, diabetic patients need to use insulin for life, with high frequency of use, large dosage, and high reimbursement ratio.
Based on the above factors, insulin may become the focus of centralized procurement.
The competitive landscape may change
It is worth noting that if insulin is officially included in centralized procurement, the competitive landscape is expected to change.
Data shows that the current domestic insulin market is still dominated by three multinational pharmaceutical companies, Sanofi, Novo Nordisk, and Eli Lilly.
The total market share of the three is expected to exceed 70%.
There are few domestic insulin companies, mainly Ganli Pharmaceutical, Tonghua Dongbao, Jiangsu Wanbang, United Laboratories, etc.
Data shows that the current domestic insulin market is still dominated by three multinational pharmaceutical companies, Sanofi, Novo Nordisk, and Eli Lilly.
The total market share of the three is expected to exceed 70%.
There are few domestic insulin companies, mainly Ganli Pharmaceutical, Tonghua Dongbao, Jiangsu Wanbang, United Laboratories, etc.
Not only in the domestic market, but also in the global market, Novo Nordisk, Sanofi and Eli Lilly are also absolute insulin giants.
In the United States and other markets, Novo Nordisk, Sanofi, and Eli Lilly have basically established an oligopoly pattern.
.
In the United States and other markets, Novo Nordisk, Sanofi, and Eli Lilly have basically established an oligopoly pattern.
.
According to Novo Nordisk’s recent 2020 financial report, the diabetes business accounted for 81% of its overall revenue, approximately 15.
66 billion U.
S.
dollars, followed by obesity and other (including short stature, hemophilia), and diabetes business.
, Novo Nordisk occupies about 30% of the global market share.
66 billion U.
S.
dollars, followed by obesity and other (including short stature, hemophilia), and diabetes business.
, Novo Nordisk occupies about 30% of the global market share.
In 2020, Novo Nordisk's revenue in China increased by 9.
7% year-on-year to US$2.
154 billion, of which diabetes drug sales increased by 11% year-on-year, and the biopharmaceutical business increased by 33% year-on-year.
Novo Nordisk's share of China's diabetes market increased from Last year's 27.
4% further increased to 29.
7%.
7% year-on-year to US$2.
154 billion, of which diabetes drug sales increased by 11% year-on-year, and the biopharmaceutical business increased by 33% year-on-year.
Novo Nordisk's share of China's diabetes market increased from Last year's 27.
4% further increased to 29.
7%.
Some analysts pointed out that with the advancement of centralized insulin procurement, domestic companies are expected to rely on price advantages to realize import substitution, achieve national market access, and gain a larger market share, thereby realizing a reshuffle of the industry's competitive landscape.
At the same time, it is expected that the market share of multinational pharmaceutical companies may be affected.
At the same time, it is expected that the market share of multinational pharmaceutical companies may be affected.
Take insulin glargine, for example, the sales data of sample hospitals in 2019 shows that Sanofi has a market share of 71%, Ganli Pharmaceuticals 28%, and United Laboratories only 1%.
However, the median bid price of domestic insulin glargine is about 80% of that of imported products, which has a price advantage.
However, the median bid price of domestic insulin glargine is about 80% of that of imported products, which has a price advantage.
Expected price decline or relatively moderate
In general, since the number of insulin manufacturers is still relatively small compared to chemical generic drugs, the competitive landscape may be relatively easing.
Industrial Securities has analyzed and pointed out that whether it is an innovative drug or a generic drug, the price of the product essentially depends on the competition.
pattern.
Industrial Securities has analyzed and pointed out that whether it is an innovative drug or a generic drug, the price of the product essentially depends on the competition.
pattern.
Take Wuhan’s first regional insulin pharmnet.
com.
cn/news/yyzb/" target="_blank">purchases .
In the end, Wuhan achieved a 43% reduction in the price of part of the winning insulin with a total purchase of 1,705,700 units.
com.
cn/news/yyzb/" target="_blank">purchases .
In the end, Wuhan achieved a 43% reduction in the price of part of the winning insulin with a total purchase of 1,705,700 units.
Compared with the four rounds of national procurement for chemical drugs, the drop of 43% of single-products is indeed relatively slow.
So far, four rounds of nationally organized drug procurement have been carried out.
The average drop of selected products is more than 50%.
The third batch The average decline of national procurement is as high as 70%, and the highest decline of single product is more than 90% in the four rounds of national procurement.
So far, four rounds of nationally organized drug procurement have been carried out.
The average drop of selected products is more than 50%.
The third batch The average decline of national procurement is as high as 70%, and the highest decline of single product is more than 90% in the four rounds of national procurement.
According to the implementation rules of Wuhan City with quantity procurement, the following principles shall be followed when grouping and quantity bargaining: insulins of the same type with different specifications belong to the same bargaining group; insulins with different premix ratios are grouped into the same bargaining group; with and without pre-filling device Insulin for filling devices (refills, etc.
) is classified into the same bargaining group.
) is classified into the same bargaining group.
Wuhan’s bargaining rules have shown that its expectations for insulin price reductions are not high—when the quotation is less than 5% of the national provincial-level online lowest price, 70% will be the agreed purchase volume; if the price is lower than 10% of the national lowest price, it will be 90% is the purchase amount.
If insulin is officially included in the national procurement, the specific procurement rules and the rate of decrease are undoubtedly the most concerned issues.
In general, the production costs and R&D costs of biopharmaceuticals are relatively high, and the decline is expected to be relatively slow after being included in centralized procurement.
At the same time, cost control and capacity supply will become the core competitiveness of relevant pharmaceutical companies.
At the same time, cost control and capacity supply will become the core competitiveness of relevant pharmaceutical companies.
However, some analysts also pointed out that because of the high gross profit margin of the original research drug, the competitiveness of the original research drug company is mainly reflected in marketing.
If the original research drug is affected by the national procurement, the impact on the marketing side may be more obvious.
If the original research drug is affected by the national procurement, the impact on the marketing side may be more obvious.
In addition to insulin, biological preparations also include recombinant proteins such as interferon, monoclonal antibodies, and blood products, vaccines and other categories.
There is a view that due to special regulatory policies and industry patterns, there is a possibility of centralized procurement for blood products and vaccines.
Lower.
There is a view that due to special regulatory policies and industry patterns, there is a possibility of centralized procurement for blood products and vaccines.
Lower.
Up to now, in addition to insulin, adalimumab, bevacizumab, and rituximab also initially have the conditions for centralized procurement.
Many industry experts believe that the centralized procurement of biological drugs is only a matter of time.
Many industry experts believe that the centralized procurement of biological drugs is only a matter of time.
Medical Network, March 10th, the centralized procurement of biological preparations, insulin may become the first batch of varieties to test the water, the market structure may face reshaping.
Advanced centralized procurement of insulin or rate
Recently, news broke out in the industry that relevant departments held a centralized drug procurement work conference and revealed that the state will carry out special volume procurement, and insulin will become the first batch of special volume procurement test water varieties.
Some analysts pointed out that it is expected that the inclusion of insulin into centralized procurement has been put on the agenda.
Insight database show that domestic production of more insulin enterprises have already reached 3 and above, are recombinant human insulin, protamine zinc recombinant human insulin, recombinant human insulin-protamine (30R), protamine recombinant human insulin (50R), Recombinant insulin glargine, in general, is mainly concentrated on the second and third generation insulins.
Insight database show that domestic production of more insulin enterprises have already reached 3 and above, are recombinant human insulin, protamine zinc recombinant human insulin, recombinant human insulin-protamine (30R), protamine recombinant human insulin (50R), Recombinant insulin glargine, in general, is mainly concentrated on the second and third generation insulins.
(Image source: Insight database)
As early as last year, on July 17, 2020, the National Medical Insurance Administration held a centralized procurement symposium to study and improve the volume procurement of insulin and other biological drugs and proprietary Chinese medicines, and analysis pointed out that insulin might be the first to enter the scope of centralized procurement.
On January 29, the State Council Information Office held a regular policy briefing.
Chen Jinfu, deputy director of the National Medical Insurance Administration, further stated that: biosimilar drugs, including large varieties of proprietary Chinese medicines, are included in the centralized procurement.
This is an institutional requirement, but the rules will It is more optimized, more targeted, and the quality is more in line with the attributes of the medicine itself.
Chen Jinfu, deputy director of the National Medical Insurance Administration, further stated that: biosimilar drugs, including large varieties of proprietary Chinese medicines, are included in the centralized procurement.
This is an institutional requirement, but the rules will It is more optimized, more targeted, and the quality is more in line with the attributes of the medicine itself.
Guosen Securities pointed out in a research report that the maturity of insulin products is high, and there is a possibility of centralized procurement in the competitive landscape; and the medical insurance catalogue basically achieves comprehensive coverage of all kinds of insulin products-the second-generation insulin is included in the Class A medical insurance, and the third-generation insulin is included in the third-generation medical insurance.
Insulin is included in Class B medical insurance (with certain reimbursement restrictions); in addition, diabetic patients need to use insulin for life, with high frequency of use, large dosage, and high reimbursement ratio.
Based on the above factors, insulin may become the focus of centralized procurement.
Insulin is included in Class B medical insurance (with certain reimbursement restrictions); in addition, diabetic patients need to use insulin for life, with high frequency of use, large dosage, and high reimbursement ratio.
Based on the above factors, insulin may become the focus of centralized procurement.
The competitive landscape may change
It is worth noting that if insulin is officially included in centralized procurement, the competitive landscape is expected to change.
Data shows that the current domestic insulin market is still dominated by three multinational pharmaceutical companies, Sanofi, Novo Nordisk, and Eli Lilly.
The total market share of the three is expected to exceed 70%.
There are few domestic insulin companies, mainly Ganli Pharmaceutical, Tonghua Dongbao, Jiangsu Wanbang, United Laboratories, etc.
Data shows that the current domestic insulin market is still dominated by three multinational pharmaceutical companies, Sanofi, Novo Nordisk, and Eli Lilly.
The total market share of the three is expected to exceed 70%.
There are few domestic insulin companies, mainly Ganli Pharmaceutical, Tonghua Dongbao, Jiangsu Wanbang, United Laboratories, etc.
Not only in the domestic market, but also in the global market, Novo Nordisk, Sanofi and Eli Lilly are also absolute insulin giants.
In the United States and other markets, Novo Nordisk, Sanofi, and Eli Lilly have basically established an oligopoly pattern.
.
In the United States and other markets, Novo Nordisk, Sanofi, and Eli Lilly have basically established an oligopoly pattern.
.
According to Novo Nordisk’s recent 2020 financial report, the diabetes business accounted for 81% of its overall revenue, approximately 15.
66 billion U.
S.
dollars, followed by obesity and other (including short stature, hemophilia), and diabetes business.
, Novo Nordisk occupies about 30% of the global market share.
66 billion U.
S.
dollars, followed by obesity and other (including short stature, hemophilia), and diabetes business.
, Novo Nordisk occupies about 30% of the global market share.
In 2020, Novo Nordisk's revenue in China increased by 9.
7% year-on-year to US$2.
154 billion, of which diabetes drug sales increased by 11% year-on-year, and the biopharmaceutical business increased by 33% year-on-year.
Novo Nordisk's share of China's diabetes market increased from Last year's 27.
4% further increased to 29.
7%.
7% year-on-year to US$2.
154 billion, of which diabetes drug sales increased by 11% year-on-year, and the biopharmaceutical business increased by 33% year-on-year.
Novo Nordisk's share of China's diabetes market increased from Last year's 27.
4% further increased to 29.
7%.
Some analysts pointed out that with the advancement of centralized insulin procurement, domestic companies are expected to rely on price advantages to realize import substitution, achieve national market access, and gain a larger market share, thereby realizing a reshuffle of the industry's competitive landscape.
At the same time, it is expected that the market share of multinational pharmaceutical companies may be affected.
At the same time, it is expected that the market share of multinational pharmaceutical companies may be affected.
Take insulin glargine, for example, the sales data of sample hospitals in 2019 shows that Sanofi has a market share of 71%, Ganli Pharmaceuticals 28%, and United Laboratories only 1%.
However, the median bid price of domestic insulin glargine is about 80% of that of imported products, which has a price advantage.
However, the median bid price of domestic insulin glargine is about 80% of that of imported products, which has a price advantage.
Expected price decline or relatively moderate
In general, since the number of insulin manufacturers is still relatively small compared to chemical generic drugs, the competitive landscape may be relatively easing.
Industrial Securities has analyzed and pointed out that whether it is an innovative drug or a generic drug, the price of the product essentially depends on the competition.
pattern.
Industrial Securities has analyzed and pointed out that whether it is an innovative drug or a generic drug, the price of the product essentially depends on the competition.
pattern.
Take Wuhan’s first regional insulin pharmnet.
com.
cn/news/yyzb/" target="_blank">purchases .
In the end, Wuhan achieved a 43% reduction in the price of part of the winning insulin with a total purchase of 1,705,700 units.
com.
cn/news/yyzb/" target="_blank">purchases .
In the end, Wuhan achieved a 43% reduction in the price of part of the winning insulin with a total purchase of 1,705,700 units.
Compared with the four rounds of national procurement for chemical drugs, the drop of 43% of single-products is indeed relatively slow.
So far, four rounds of nationally organized drug procurement have been carried out.
The average drop of selected products is more than 50%.
The third batch The average decline of national procurement is as high as 70%, and the highest decline of single product is more than 90% in the four rounds of national procurement.
So far, four rounds of nationally organized drug procurement have been carried out.
The average drop of selected products is more than 50%.
The third batch The average decline of national procurement is as high as 70%, and the highest decline of single product is more than 90% in the four rounds of national procurement.
According to the implementation rules of Wuhan City with quantity procurement, the following principles shall be followed when grouping and quantity bargaining: insulins of the same type with different specifications belong to the same bargaining group; insulins with different premix ratios are grouped into the same bargaining group; with and without pre-filling device Insulin for filling devices (refills, etc.
) is classified into the same bargaining group.
) is classified into the same bargaining group.
Wuhan’s bargaining rules have shown that its expectations for insulin price reductions are not high—when the quotation is less than 5% of the national provincial-level online lowest price, 70% will be the agreed purchase volume; if the price is lower than 10% of the national lowest price, it will be 90% is the purchase amount.
If insulin is officially included in the national procurement, the specific procurement rules and the rate of decrease are undoubtedly the most concerned issues.
In general, the production costs and R&D costs of biopharmaceuticals are relatively high, and the decline is expected to be relatively slow after being included in centralized procurement.
At the same time, cost control and capacity supply will become the core competitiveness of relevant pharmaceutical companies.
At the same time, cost control and capacity supply will become the core competitiveness of relevant pharmaceutical companies.
However, some analysts also pointed out that because of the high gross profit margin of the original research drug, the competitiveness of the original research drug company is mainly reflected in marketing.
If the original research drug is affected by the national procurement, the impact on the marketing side may be more obvious.
If the original research drug is affected by the national procurement, the impact on the marketing side may be more obvious.
In addition to insulin, biological preparations also include recombinant proteins such as interferon, monoclonal antibodies, and blood products, vaccines and other categories.
There is a view that due to special regulatory policies and industry patterns, there is a possibility of centralized procurement for blood products and vaccines.
Lower.
There is a view that due to special regulatory policies and industry patterns, there is a possibility of centralized procurement for blood products and vaccines.
Lower.
Up to now, in addition to insulin, adalimumab, bevacizumab, and rituximab also initially have the conditions for centralized procurement.
Many industry experts believe that the centralized procurement of biological drugs is only a matter of time.
Many industry experts believe that the centralized procurement of biological drugs is only a matter of time.
Medical Network, March 10th, the centralized procurement of biological preparations, insulin may become the first batch of varieties to test the water, the market structure may face reshaping.
Advanced centralized procurement of insulin or rate
Advanced centralized procurement of insulin or rate Recently, news broke out in the industry that relevant departments held a centralized drug procurement work conference and revealed that the state will carry out special volume procurement, and insulin will become the first batch of special volume procurement test water varieties.
Medicine, medicine, medicine Some analysts pointed out that it is expected that the inclusion of insulin into centralized procurement has been put on the agenda.
Insight database show that domestic production of more insulin enterprises have already reached 3 and above, are recombinant human insulin, protamine zinc recombinant human insulin, recombinant human insulin-protamine (30R), protamine recombinant human insulin (50R), Recombinant insulin glargine, in general, is mainly concentrated on the second and third generation insulins.
Enterprise business enterpriseInsight database show that domestic production of more insulin enterprises have already reached 3 and above, are recombinant human insulin, protamine zinc recombinant human insulin, recombinant human insulin-protamine (30R), protamine recombinant human insulin (50R), Recombinant insulin glargine, in general, is mainly concentrated on the second and third generation insulins.
(Image source: Insight database)
As early as last year, on July 17, 2020, the National Medical Insurance Administration held a centralized procurement symposium to study and improve the volume procurement of insulin and other biological drugs and proprietary Chinese medicines, and analysis pointed out that insulin might be the first to enter the scope of centralized procurement.
On January 29, the State Council Information Office held a regular policy briefing.
Chen Jinfu, deputy director of the National Medical Insurance Administration, further stated that: biosimilar drugs, including large varieties of proprietary Chinese medicines, are included in the centralized procurement.
This is an institutional requirement, but the rules will It is more optimized, more targeted, and the quality is more in line with the attributes of the medicine itself.
Chen Jinfu, deputy director of the National Medical Insurance Administration, further stated that: biosimilar drugs, including large varieties of proprietary Chinese medicines, are included in the centralized procurement.
This is an institutional requirement, but the rules will It is more optimized, more targeted, and the quality is more in line with the attributes of the medicine itself.
Guosen Securities pointed out in a research report that the maturity of insulin products is high, and there is a possibility of centralized procurement in the competitive landscape; and the medical insurance catalogue basically achieves comprehensive coverage of all kinds of insulin products-the second-generation insulin is included in the Class A medical insurance, and the third-generation insulin is included in the third-generation medical insurance.
Insulin is included in Class B medical insurance (with certain reimbursement restrictions); in addition, diabetic patients need to use insulin for life, with high frequency of use, large dosage, and high reimbursement ratio.
Based on the above factors, insulin may become the focus of centralized procurement.
Insulin is included in Class B medical insurance (with certain reimbursement restrictions); in addition, diabetic patients need to use insulin for life, with high frequency of use, large dosage, and high reimbursement ratio.
Based on the above factors, insulin may become the focus of centralized procurement.
The competitive landscape may change
The competitive landscape may change It is worth noting that if insulin is officially included in centralized procurement, the competitive landscape is expected to change.
Data shows that the current domestic insulin market is still dominated by three multinational pharmaceutical companies, Sanofi, Novo Nordisk, and Eli Lilly.
The total market share of the three is expected to exceed 70%.
There are few domestic insulin companies, mainly Ganli Pharmaceutical, Tonghua Dongbao, Jiangsu Wanbang, United Laboratories, etc.
Data shows that the current domestic insulin market is still dominated by three multinational pharmaceutical companies, Sanofi, Novo Nordisk, and Eli Lilly.
The total market share of the three is expected to exceed 70%.
There are few domestic insulin companies, mainly Ganli Pharmaceutical, Tonghua Dongbao, Jiangsu Wanbang, United Laboratories, etc.
Not only in the domestic market, but also in the global market, Novo Nordisk, Sanofi and Eli Lilly are also absolute insulin giants.
In the United States and other markets, Novo Nordisk, Sanofi, and Eli Lilly have basically established an oligopoly pattern.
.
In the United States and other markets, Novo Nordisk, Sanofi, and Eli Lilly have basically established an oligopoly pattern.
.
According to Novo Nordisk’s recent 2020 financial report, the diabetes business accounted for 81% of its overall revenue, approximately 15.
66 billion U.
S.
dollars, followed by obesity and other (including short stature, hemophilia), and diabetes business.
, Novo Nordisk occupies about 30% of the global market share.
66 billion U.
S.
dollars, followed by obesity and other (including short stature, hemophilia), and diabetes business.
, Novo Nordisk occupies about 30% of the global market share.
In 2020, Novo Nordisk's revenue in China increased by 9.
7% year-on-year to US$2.
154 billion, of which diabetes drug sales increased by 11% year-on-year, and the biopharmaceutical business increased by 33% year-on-year.
Novo Nordisk's share of China's diabetes market increased from Last year's 27.
4% further increased to 29.
7%.
7% year-on-year to US$2.
154 billion, of which diabetes drug sales increased by 11% year-on-year, and the biopharmaceutical business increased by 33% year-on-year.
Novo Nordisk's share of China's diabetes market increased from Last year's 27.
4% further increased to 29.
7%.
Some analysts pointed out that with the advancement of centralized insulin procurement, domestic companies are expected to rely on price advantages to realize import substitution, achieve national market access, and gain a larger market share, thereby realizing a reshuffle of the industry's competitive landscape.
At the same time, it is expected that the market share of multinational pharmaceutical companies may be affected.
At the same time, it is expected that the market share of multinational pharmaceutical companies may be affected.
Take insulin glargine, for example, the sales data of sample hospitals in 2019 shows that Sanofi has a market share of 71%, Ganli Pharmaceuticals 28%, and United Laboratories only 1%.
However, the median bid price of domestic insulin glargine is about 80% of that of imported products, which has a price advantage.
Hospital hospital hospitalHowever, the median bid price of domestic insulin glargine is about 80% of that of imported products, which has a price advantage.
Expected price decline or relatively moderate
Expected price decline or relatively moderate In general, since the number of insulin manufacturers is still relatively small compared to chemical generic drugs, the competitive landscape may be relatively easing.
Industrial Securities has analyzed and pointed out that whether it is an innovative drug or a generic drug, the price of the product essentially depends on the competition.
pattern.
Industrial Securities has analyzed and pointed out that whether it is an innovative drug or a generic drug, the price of the product essentially depends on the competition.
pattern.
Take Wuhan’s first regional insulin pharmnet.
com.
cn/news/yyzb/" target="_blank">purchases .
In the end, Wuhan achieved a 43% reduction in the price of part of the winning insulin with a total purchase of 1,705,700 units.
pharmnet. com.
cn/news/yyzb/" target="_blank">purchases .
In the end, Wuhan achieved a 43% reduction in the price of part of the winning insulin with a total purchase of 1,705,700 units.
com.
cn/news/yyzb/" target="_blank">Procurementpharmnet.
com.
cn/news/yyzb/" target="_blank"> Procurement Procurement
Compared with the four rounds of national procurement for chemical drugs, the drop of 43% of single-products is indeed relatively slow.
So far, four rounds of nationally organized drug procurement have been carried out.
The average drop of selected products is more than 50%.
The third batch The average decline of national procurement is as high as 70%, and the highest decline of single product is more than 90% in the four rounds of national procurement.
So far, four rounds of nationally organized drug procurement have been carried out.
The average drop of selected products is more than 50%.
The third batch The average decline of national procurement is as high as 70%, and the highest decline of single product is more than 90% in the four rounds of national procurement.
According to the implementation rules of Wuhan City with quantity procurement, the following principles shall be followed when grouping and quantity bargaining: insulins of the same type with different specifications belong to the same bargaining group; insulins with different premix ratios are grouped into the same bargaining group; with and without pre-filling device Insulin for filling devices (refills, etc.
) is classified into the same bargaining group.
) is classified into the same bargaining group.
Wuhan’s bargaining rules have shown that its expectations for insulin price reductions are not high—when the quotation is less than 5% of the national provincial-level online lowest price, 70% will be the agreed purchase volume; if the price is lower than 10% of the national lowest price, it will be 90% is the purchase amount.
If insulin is officially included in the national procurement, the specific procurement rules and the rate of decrease are undoubtedly the most concerned issues.
In general, the production costs and R&D costs of biopharmaceuticals are relatively high, and the decline is expected to be relatively slow after being included in centralized procurement.
At the same time, cost control and capacity supply will become the core competitiveness of relevant pharmaceutical companies.
At the same time, cost control and capacity supply will become the core competitiveness of relevant pharmaceutical companies.
However, some analysts also pointed out that because of the high gross profit margin of the original research drug, the competitiveness of the original research drug company is mainly reflected in marketing.
If the original research drug is affected by the national procurement, the impact on the marketing side may be more obvious.
If the original research drug is affected by the national procurement, the impact on the marketing side may be more obvious.
In addition to insulin, biological preparations also include recombinant proteins such as interferon, monoclonal antibodies, and blood products, vaccines and other categories.
There is a view that due to special regulatory policies and industry patterns, there is a possibility of centralized procurement for blood products and vaccines.
Lower.
There is a view that due to special regulatory policies and industry patterns, there is a possibility of centralized procurement for blood products and vaccines.
Lower.
Up to now, in addition to insulin, adalimumab, bevacizumab, and rituximab also initially have the conditions for centralized procurement.
Many industry experts believe that the centralized procurement of biological drugs is only a matter of time.
Many industry experts believe that the centralized procurement of biological drugs is only a matter of time.
